SIGA

SIGA Technologies Inc

Add to Watchlist

Advanced Chart

7.260

+0.66(10.000%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

7.800

Open

6.990

VWAP

7.44

Vol

1.35M

Mkt Cap

519.86M

Low

6.885

Amount

10.02M

EV/EBITDA(TTM)

5.49

Total Shares

71.12M

289.05M

EV/OCF(TTM)

2.43

P/S(TTM)

2.64

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company. The Company is focused on the development of medicines to treat and prevent infectious diseases. Its flagship product, TPOXX (tecovirimat), is an antiviral medicine approved in the United States and Canada for the treatment of smallpox and authorized in Europe, the United Kingdom, and Japan for the treatment of smallpox, monkeypox (mpox), cowpox, and vaccinia complications. TPOXX specifically inhibits the activity of a protein called VP37, found on the surface of all orthopoxviruses. This prevents the virus from leaving infected cells, slowing the spread of the infection and limiting it to a point where the immune system can clear the virus. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox.

Valuation Metrics

The current forward P/E ratio for SIGA Technologies Inc (SIGA.O) is 7.25, compared to its 5-year average forward P/E of 8.00. For a more detailed relative valuation and DCF analysis to assess SIGA Technologies Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

8.00

Current PE

7.25

Overvalued PE

13.15

Undervalued PE

2.84

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

4.20

Current EV/EBITDA

3.97

Overvalued EV/EBITDA

8.25

Undervalued EV/EBITDA

0.15

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

3.42

Current PS

3.16

Overvalued PS

5.40

Undervalued PS

1.45

Financials

Annual

Quarterly

FY2025Q2

YoY :

+271.92%

81.12M

Total Revenue

FY2025Q2

YoY :

+4130.25%

45.68M

Operating Profit

FY2025Q2

YoY :

+1836.20%

35.48M

Net Income after Tax

FY2025Q2

YoY :

+1533.33%

0.49

EPS - Diluted

FY2025Q2

YoY :

+960.03%

63.08M

Free Cash Flow

FY2025Q2

YoY :

+57.29%

68.50

Gross Profit Margin - %

FY2025Q2

YoY :

+55.33%

66.25

FCF Margin - %

FY2025Q2

YoY :

+420.71%

43.74

Net Margin - %

FY2025Q2

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

242.6K

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

326.6K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

SIGA News & Events

Events Timeline

2025-04-08 (ET)

2025-04-08

07:36:54

Siga Technologies declares special cash dividend of 60c per share

2025-03-18 (ET)

2025-03-18

07:36:01

Siga Technologies appoints General John Keane to its Board of Directors

2025-03-12 (ET)

2025-03-12

11:42:09

NIH: Siga's tecovirimat safe, but ineffective as treatment for Clade II Mpox

News

2.0

07-16NASDAQ.COM

Siga Technologies Inc. (SIGA) Dips More Than Broader Market: What You Should Know

2.0

06-13NASDAQ.COM

Why Siga Technologies Inc. (SIGA) Dipped More Than Broader Market Today

8.0

04-08SeekingAlpha

SIGA Technologies declares $0.60 dividend

People Also Watch

Summit Midstream Corp

Keros Therapeutics Inc

Mereo BioPharma Group PLC

Hudson Pacific Properties Inc

Pennantpark Investment Corp

7.290

USD

+0.83%

FAQ

What is SIGA Technologies Inc (SIGA) stock price today?

The current price of SIGA is 7.26 USD — it has increased 10 % in the last trading day.

SIGA

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

SIGA News & Events

Events Timeline

News

People Also Watch

FAQ

What is SIGA Technologies Inc (SIGA) stock price today?

What is SIGA Technologies Inc (SIGA)'s business?

What is the price predicton of SIGA Stock?

What is SIGA Technologies Inc (SIGA)'s revenue for the last quarter?

What is SIGA Technologies Inc (SIGA)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for SIGA Technologies Inc (SIGA)'s fundamentals?

How many employees does SIGA Technologies Inc (SIGA). have?

What is SIGA Technologies Inc (SIGA) market cap?